RecruitingPhase 2NCT07275840

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

An Open-label, Multicenter, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Intravitreal Injection of IBI302 in Participants With Neovascular Age-related Macular Degeneration

Sponsor

Innovent Biologics Technology Limited (Shanghai R&D Center)

Enrollment

800 participants

Start Date

Dec 5, 2025

Study Type

INTERVENTIONAL

Conditions

Neovascular Age-related Macular Degeneration

Summary

This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IBI302 8mg dose for people with neovascular age-related macular degeneration. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIBI302 8mg dose

8 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks.